(Reuters) - ZURICH, July 9 - Pharmaceutical group Novartis said on Monday it had received U.S. approval for Exelon Patch, which delivers a treatment for Alzheimer's disease through a skin patch instead of an oral capsule.
The medication was submitted for review in the European Union in late 2006, Novartis said.
Read more at Reuters.com Market News
The medication was submitted for review in the European Union in late 2006, Novartis said.
Read more at Reuters.com Market News
No comments:
Post a Comment